Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient tumour regressions and resistance due to increased...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David H. Peng, B. Leticia Rodriguez, Lixia Diao, Pierre-Olivier Gaudreau, Aparna Padhye, Jessica M. Konen, Joshua K. Ochieng, Caleb A. Class, Jared J. Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren A. Byers, Don. L. Gibbons
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c550e9da14dd40faac0c52202ab9def2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c550e9da14dd40faac0c52202ab9def2
record_format	dspace
spelling	oai:doaj.org-article:c550e9da14dd40faac0c52202ab9def22021-12-02T16:57:12ZTh17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers10.1038/s41467-021-22875-w2041-1723https://doaj.org/article/c550e9da14dd40faac0c52202ab9def22021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22875-whttps://doaj.org/toc/2041-1723Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient tumour regressions and resistance due to increased infiltration of Th17 cells and that the triple therapy targeting MEK, PD-L1 and IL-17 produced better in vivo responses.David H. PengB. Leticia RodriguezLixia DiaoPierre-Olivier GaudreauAparna PadhyeJessica M. KonenJoshua K. OchiengCaleb A. ClassJared J. FradetteLaura GibsonLimo ChenJing WangLauren A. ByersDon. L. GibbonsNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q David H. Peng B. Leticia Rodriguez Lixia Diao Pierre-Olivier Gaudreau Aparna Padhye Jessica M. Konen Joshua K. Ochieng Caleb A. Class Jared J. Fradette Laura Gibson Limo Chen Jing Wang Lauren A. Byers Don. L. Gibbons Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
description	Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient tumour regressions and resistance due to increased infiltration of Th17 cells and that the triple therapy targeting MEK, PD-L1 and IL-17 produced better in vivo responses.
format	article
author	David H. Peng B. Leticia Rodriguez Lixia Diao Pierre-Olivier Gaudreau Aparna Padhye Jessica M. Konen Joshua K. Ochieng Caleb A. Class Jared J. Fradette Laura Gibson Limo Chen Jing Wang Lauren A. Byers Don. L. Gibbons
author_facet	David H. Peng B. Leticia Rodriguez Lixia Diao Pierre-Olivier Gaudreau Aparna Padhye Jessica M. Konen Joshua K. Ochieng Caleb A. Class Jared J. Fradette Laura Gibson Limo Chen Jing Wang Lauren A. Byers Don. L. Gibbons
author_sort	David H. Peng
title	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
title_short	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
title_full	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
title_fullStr	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
title_full_unstemmed	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
title_sort	th17 cells contribute to combination mek inhibitor and anti-pd-l1 therapy resistance in kras/p53 mutant lung cancers
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c550e9da14dd40faac0c52202ab9def2
work_keys_str_mv	AT davidhpeng th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT bleticiarodriguez th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT lixiadiao th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT pierreoliviergaudreau th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT aparnapadhye th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT jessicamkonen th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT joshuakochieng th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT calebaclass th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT jaredjfradette th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT lauragibson th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT limochen th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT jingwang th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT laurenabyers th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers AT donlgibbons th17cellscontributetocombinationmekinhibitorandantipdl1therapyresistanceinkrasp53mutantlungcancers
_version_	1718382589845176320

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Ejemplares similares